WT-1 A1 is an attractive target for immunotherapy in patients with pancreatic adenocarcinoma. References: Terashima T, Mizukoshi E, Arai K, Yamashita T, Yoshida M, Ota H, Onishi I, Kayahara M, Ohtsubo K, Kagaya T, Honda M, Kaneko S. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Cancer Immunol Immunother. 2014 May;63(5):479-89. doi: 10.1007/s00262-014-1529-8. Epub 2014 Mar 16. PubMed PMID: 24633336.

纯度：≥98%

CAS：852243-39-1